(S)-6-(2-(Benzo[D][1,3]Dioxol-5-Yl)Ethyl)-4-Methoxy-5,6-Dihydro-2H-Pyran-2-One (S)-6-(2-(苯并[d][1,3]二氧戊环-5-基)乙基)-4-甲氧基-5,6-二氢-2H-吡喃-2-酮
CAS 19902-91-1 MFCD00221731
化学结构图
SMILES: COC1C[C@H](CCC2C=C3OCOC3=CC=2)OC(=O)C=1
化学属性
| Mol. Formula | C15H16O5 |
|---|---|
| Mol. Weight | 276.31 |
别名和识别编码
| Chemical Name | (S)-6-(2-(Benzo[D][1,3]Dioxol-5-Yl)Ethyl)-4-Methoxy-5,6-Dihydro-2H-Pyran-2-One |
|---|---|
| Synonym | 2H-Pyran-2-one, 6-(2-(1,3-benzodioxol-5-yl)ethyl)-5,6-dihydro-4-methoxy-, 7,8-Dihydromethysticin Dihydromethysticin (+)-Dihydromethysticin 6-[2-(1,3-Benzodioxol-5-yl)ethyl]-4-methoxy-5,6-dihydro-2H-pyran-2-one DHM |
| CAS Number | 19902-91-1 |
| MDL Number | MFCD00221731 |
| Beilstein Registry Number | 91699 |
| Chemical Name Translation | (S)-6-(2-(苯并[d][1,3]二氧戊环-5-基)乙基)-4-甲氧基-5,6-二氢-2H-吡喃-2-酮 |
信息真实价格透明
资金保障
专业采购外包团队在线服务
信息真实价格透明
资金保障
专业采购外包团队在线服务
品牌质保精细包装
现货库存
一流品牌服务
分类
- {SNA} A - D, Alphabetical, Analytical Standards, Analytical/Chromatography, Chromatography, Life Sciences Standards, Phenylpropanes, Phytopharma Standards, Piper, Standards by Plant Genus, Substance Classification
相关文献及参考
- [2]. Walden J, et al. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 1997 May;21(4):697-706.
- [3]. Sarris J, et al. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry. 2011 Jan;45(1):27-35.
- [1]. Ma Y, et al. Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23. Drug Metab Dispos. 2004 Nov;32(11):1317-24.
- [1]. Ma Y, et al. Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23. Drug Metab Dispos. 2004 Nov;32(11):1317-24.
- [2]. Walden J, et al. Effects of kawain and dihydromethysticin on field potential changes in the hippocampus. Prog Neuropsychopharmacol Biol Psychiatry. 1997 May;21(4):697-706.
- [3]. Sarris J, et al. Kava: a comprehensive review of effica
安全信息
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Oral SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 1050 mg/kg TOXIC EFFECTS : Behavioral - muscle weakness Behavioral - ataxia Lungs, Thorax, or Respiration - other changes REFERENCE : AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 138,505,1962
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - mouse DOSE/DURATION : 420 mg/kg TOXIC EFFECTS : Details of toxic effects not reported other than lethal dose value REFERENCE : EXPEAM Experientia. (Birkhaeuser Verlag, POB 133, CH-4010 Basel, Switzerland) V.1- 1945- Volume(issue)/page/year: 26,283,1970
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Rodent - rabbit DOSE/DURATION : 300 mg/kg TOXIC EFFECTS : Behavioral - muscle weakness Behavioral - muscle contraction or spasticity Gastrointestinal - nausea or vomiting REFERENCE : AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology, De Pintelaan 185, B-9000 Ghent, Belgium) V.4- 1898- Volume(issue)/page/year: 138,505,1962
TYPE OF TEST : LD50 - Lethal dose, 50 percent kill ROUTE OF EXPOSURE : Intraperitoneal SPECIES OBSERVED : Mammal - dog DOSE/DURATION : >200 mg/kg TOXIC EFFECTS : Behavioral - muscle weakness Behavioral - muscle contraction or spasticity Gastrointestinal - nausea or vomiting REFERENCE : AIPTAK Archives Internationales de Pharmacodynamie et de Therapie. (Heymans Institute of Pharmacology,
